Pancreatic cancer treating Anviron looks to commence clinical trial

a Newport Beach cancer treatment company, is raising $500,000 for the development of a pancreatic cancer drug.

About 75% of pancreatic cancer patients die within a year of diagnosis, according to Anviron founder and President Bradley Morrison.

Anviron has developed a means to inhibit the protein that triggers the proliferation of pancreatic cells. The company has completed mouse studies in which its drug outperformed the standard of care by dissolving pancreatic cancer tumors within two weeks. Now, Anviron is looking to commence a canine clinical trial, which, if successful, will result in “virtually automatic FDA conditional approvals,” Morrison said.

Anviron’s drug, ANV221, received orphan drug designation from the FDA “when we demonstrated superior performance over current chemotherapies in pancreatic mouse models,” Morrison told the Business Journal.

Morrison, who co-founded the company in 2020, currently works as the director of worldwide sales for the converted freighter program at Boeing Co. (NYSE: BA). He also serves as a board member of Yorba Linda medical equipment manufacturer MediPines Corp. Morrison previously worked as the director of business development at Santa Ana e-commerce company Arbitrel.